GLOBAL
Alnylam is committed to supporting and partnering with the healthcare community across many disease areas. This includes providing information on our research and treatments in development.
Acting “UPSTREAM” of Today’s Medicines
With investigational RNAi therapeutics, we believe it may be possible to block the production of disease-causing proteins before they are made.
Our Pipeline
Our robust pipeline includes investigational RNAi therapeutics for rare, genetic, cardio-metabolic, infectious and CNS and ocular diseases.
Late Stage
Learn more about our investigational therapies in hereditary ATTR amyloidosis, hemophilia, hypercholesterolemia, and primary hyperoxaluria type 1.
Alnylam Grant Information
Alnylam is committed to supporting the medical and scientific understanding of our therapeutic areas of interest for healthcare professionals. Additionally, we are committed to supporting educational programs and initiatives spearheaded by organizations focused on patient advocacy, community education and support, and other scientific efforts related to our therapeutic areas of interest. To learn more about grants, sponsorships, or how to submit a grant request, visit our grants page.
Access to Investigational Medicines
Alnylam is dedicated to developing new therapies that have a positive impact on patient health, and to serving patients, patient families, and patient communities through education, empathy, and awareness. We understand that there are seriously ill patients who will not be eligible for our clinical trials and may not have options for alternative therapies, including investigational therapies in trials being conducted by other sponsors. In these circumstances, Alnylam will consider providing a requesting physician with pre-approval access to a specific Alnylam investigational medicine, for the treatment of an individual patient outside of a clinical trial, when certain conditions are met.
To read our statement on access to investigational medicines, click here.
CLINICAL TRIALS
Learn more about Alnylam-sponsored clinical trials your patients may be eligible for.
ALNYLAM ACT
Through Alnylam Act®, healthcare professionals can request genetic testing and counseling for hATTR amyloidosis, acute hepatic porphyria, or primary hyperoxaluria type 1 for individuals meeting certain criteria.
ALNYLAM ASSIST
Alnylam Assist® offers patients personalized support throughout their treatment with an Alnylam product.
